S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Pliant Therapeutics Stock Forecast, Price & News

-0.47 (-4.20%)
(As of 01/21/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
120,937 shs
Average Volume
132,453 shs
Market Capitalization
$386.70 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive PLRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Pliant Therapeutics logo

About Pliant Therapeutics

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avÃ6 and avÃ1 integrins, which is in Phase II single ascending dose/multiple ascending dose trails and completed Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, a small-molecule selective inhibitor of avÃ1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.


Pliant Therapeutics, Inc. (PLRX)
December 17, 2021 |  realmoney.thestreet.com
Pliant Stock Moves Higher On Positive Data From Pulmonary Fibrosis Trial
September 7, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$41.82 million
Book Value
$7.98 per share


Net Income
$-41.53 million
Net Margins
Pretax Margin




Free Float
Market Cap
$386.70 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.03 out of 5 stars

Medical Sector

596th out of 1,418 stocks

Pharmaceutical Preparations Industry

286th out of 684 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Pliant Therapeutics (NASDAQ:PLRX) Frequently Asked Questions

Is Pliant Therapeutics a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pliant Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Pliant Therapeutics stock.
View analyst ratings for Pliant Therapeutics
or view top-rated stocks.

When is Pliant Therapeutics' next earnings date?

Pliant Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 15th 2022.
View our earnings forecast for Pliant Therapeutics

How were Pliant Therapeutics' earnings last quarter?

Pliant Therapeutics, Inc. (NASDAQ:PLRX) released its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.75) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by $0.06. The firm had revenue of $1.61 million for the quarter, compared to the consensus estimate of $2.50 million. Pliant Therapeutics had a negative net margin of 914.12% and a negative trailing twelve-month return on equity of 36.28%.
View Pliant Therapeutics' earnings history

What price target have analysts set for PLRX?

7 Wall Street analysts have issued 1-year target prices for Pliant Therapeutics' shares. Their forecasts range from $38.00 to $63.00. On average, they expect Pliant Therapeutics' stock price to reach $46.17 in the next year. This suggests a possible upside of 330.3% from the stock's current price.
View analysts' price targets for Pliant Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Pliant Therapeutics' key executives?

Pliant Therapeutics' management team includes the following people:
  • Prof. Bernard Coulie M.B.A., Ph.D., M.D., MBA, Pres, CEO & Director (Age 55, Pay $895.27k)
  • Mr. Johannes P. Hull, Chief Bus. Officer (Age 46, Pay $560.84k)
  • Dr. Éric Lefebvre M.D., Chief Medical Officer (Age 57, Pay $646.04k)
  • Dr. Rik Derynck, Scientific Founder & Member of Scientific Advisory Board
  • Mr. Dean Sheppard M.D., Scientific Founder & Member of Scientific Advisory Board
  • Mr. Bill DeGrado Ph.D., Scientific Founder & Member of Scientific Advisory Board
  • Mr. Hal Chapman M.D., Scientific Founder & Member of Scientific Advisory Board
  • Dr. Keith Lamont Cummings M.B.A., M.D., Chief Financial Officer (Age 44)
  • Mr. Craig D. Muir, Interim Chief Technology Officer
  • Mr. Christopher S. Keenan, VP of Investor Relations & Corp. Communications

What other stocks do shareholders of Pliant Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pliant Therapeutics investors own include Pfizer (PFE), Ampio Pharmaceuticals (AMPE), CrowdStrike (CRWD), Trevena (TRVN), AbbVie (ABBV), Abbott Laboratories (ABT), Archer-Daniels-Midland (ADM), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN).

When did Pliant Therapeutics IPO?

(PLRX) raised $90 million in an initial public offering (IPO) on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler acted as the underwriters for the IPO and Needham & Company was co-manager.

What is Pliant Therapeutics' stock symbol?

Pliant Therapeutics trades on the NASDAQ under the ticker symbol "PLRX."

Who are Pliant Therapeutics' major shareholders?

Pliant Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Russell Investments Group Ltd. (0.09%) and Clear Creek Financial Management LLC (0.03%). Company insiders that own Pliant Therapeutics stock include Bernard Coulie, Eric Lefebvre, Keith Lamont Cummings and Matthew Dunnigan.
View institutional ownership trends for Pliant Therapeutics

Which institutional investors are buying Pliant Therapeutics stock?

PLRX stock was acquired by a variety of institutional investors in the last quarter, including Clear Creek Financial Management LLC, and Russell Investments Group Ltd..
View insider buying and selling activity for Pliant Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Pliant Therapeutics?

Shares of PLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pliant Therapeutics' stock price today?

One share of PLRX stock can currently be purchased for approximately $10.73.

How much money does Pliant Therapeutics make?

Pliant Therapeutics has a market capitalization of $386.70 million and generates $41.82 million in revenue each year. The company earns $-41.53 million in net income (profit) each year or ($2.57) on an earnings per share basis.

How many employees does Pliant Therapeutics have?

Pliant Therapeutics employs 78 workers across the globe.

What is Pliant Therapeutics' official website?

The official website for Pliant Therapeutics is pliantrx.com.

Where are Pliant Therapeutics' headquarters?

Pliant Therapeutics is headquartered at 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Pliant Therapeutics?

Pliant Therapeutics' mailing address is 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-481-6770 or via email at [email protected].

This page was last updated on 1/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.